Analytical development for rapid response vaccines: start early, think ahead

Vaccine Insights 2022; 1(1), 1–3

DOI: 10.18609/vac.2022.001

Published: 20 May 2022
Viewpoint
Anna Särnefält, Ingrid Kromann

“As highlighted by the COVID-19 pandemic, early analytical development is key for the rapid scale-up of new vaccines. Careful consideration of assay development throughout the pipeline can expedite technology transfer, avoid costly missteps, and produce vaccines faster to fight future pandemics.”

The COVID-19 pandemic prompted laboratories around the globe to start developing vaccines against SARS-CoV-2. One important lesson from this unprecedented effort is that to achieve worldwide mass vaccination in record time, an early focus on assay development is key.